Logo Logo

Category Archives: "INforMS"

  1. Home
  2. INforMS
  3. Page 29
Oct 08, 2015
Results from ZINBRYTA phase 3 DECIDE study presented at ECTRIMS
INforMS
Results from ZINBRYTA™ (Daclizumab High-Yield Process) Phase 3 DECIDE Study Highlighting Efficacy Compared to Interferon Beta-1a [...]
Elizabeth Porco
Read More
...21
0
Oct 07, 2015
New analysis suggests Aubagio slows brain atrophy in people with Relapsing MS
INforMS, Partners
New Analysis Suggests Aubagio® (teriflunomide) Slows Brain Atrophy in People with Relapsing Multiple Sclerosis Additional MRI data on [...]
Elizabeth Porco
Read More
...20
0
Oct 07, 2015
Data show effects of TECFIDERA in newly-diagnosed and early disease course multiple sclerosis patients
INforMS, Partners
New Data Show Strong, Sustained Effects of TECFIDERA® (Dimethyl Fumarate) in Newly-Diagnosed and Early Disease Course Multiple Sclerosis [...]
Elizabeth Porco
Read More
...23
0
Oct 06, 2015
Opexa announces granting of new t-cell patents covering tcelna
INforMS
THE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized [...]
Elizabeth Porco
Read More
...25
0
Oct 05, 2015
Genzyme introduces “vs.MS”, a global initiative
INforMS, MS Community, Partners
Genzyme Introduces vs.MS, a Global Initiative Aimed at Uncovering the Often Unspoken Challenges of MS to Drive Better Informed [...]
Elizabeth Porco
Read More
...24
0
Sep 27, 2015
Genentech’s Ocrelizumab to show efficacy in people with PPMS in large phase III study
INforMS, Partners
Genentech’s Ocrelizumab First Investigational Medicine to Show Efficacy in People with Primary Progressive Multiple Sclerosis in Large [...]
Elizabeth Porco
Read More
...23
0
Sep 25, 2015
Bayer receives FDA approval for BETACONNECT
INforMS, Partners
Intended for U.S. Media Only Whippany, N.J., September 25, 2015 – Bayer HealthCare announced today that the U.S. Food and Drug [...]
Elizabeth Porco
Read More
...25
0
Aug 21, 2015
Novartis acquires all remaining rights to GSK Ofatumumab to develop treatments for multiple sclerosis
INforMS, Partners
Novartis acquires all remaining rights to GSK’s Ofatumumab to develop treatments for MS and other autoimmune indications Novartis [...]
Elizabeth Porco
Read More
...25
0
Aug 09, 2015
EMD Serono and Opexa amend agreement to support ongoing development of Tcelna for multiple sclerosis
INforMS, Partners
EMD Serono and Opexa Amend Agreement to Support Ongoing Development of Tcelna (imilecleucel-T) for Multiple Sclerosis Personalized [...]
Elizabeth Porco
Read More
...20
0
Aug 03, 2015
Pfizer & Synthon enter Into U.S. commercialization agreement for treatment of multiple sclerosis
INforMS
Pfizer Inc. and Synthon, an international pharmaceutical company specializing in the development of complex generic medicines, today [...]
Elizabeth Porco
Read More
...22
0
  • (201) 487-1050
  • 3 University Plz Dr Ste 116, Hackensack, NJ 07601
  • info@mscare.org

CMSC provides leadership in clinical research and education; develops vehicles to share information and knowledge among members; disseminates information to the health care community and to persons affected by MS.

Contact Us
Contact Us
I have a question about
First
Last

Feel Free To contact Us
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam molestie, tellus id pellen tesque feugiat, sem sem cursus orci, a placerat ante ante nec massa. consectetuer adipiscing elit.

+1-222-333-4444

New York, NY 10123 USA

Mon - Sat 9:00 AM